HC Wainwright Lowers Earnings Estimates for NervGen Pharma

NervGen Pharma (NASDAQ:NGEN) – Equities researchers at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of NervGen Pharma in a report released on Tuesday, July 14th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.11) per share for the quarter, down from their previous forecast of ($0.09). HC Wainwright currently has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for NervGen Pharma’s Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.56) EPS.

A number of other equities analysts have also weighed in on NGEN. TD Cowen began coverage on NervGen Pharma in a research note on Thursday, June 11th. They set a “buy” rating on the stock. Wall Street Zen lowered NervGen Pharma from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Zacks Research raised shares of NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th. Stifel Nicolaus raised shares of NervGen Pharma to a “strong-buy” rating in a research report on Thursday, April 23rd. Finally, Weiss Ratings assumed coverage on shares of NervGen Pharma in a report on Friday, April 24th. They issued a “sell (d-)” rating for the company. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, NervGen Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

NervGen Pharma Stock Down 1.2%

NGEN stock opened at $1.67 on Thursday. The firm has a 50 day moving average of $2.32. The stock has a market capitalization of $134.65 million and a price-to-earnings ratio of -18.56. NervGen Pharma has a 1 year low of $1.61 and a 1 year high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last announced its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.